United Therapeutics Corporation - Common Stock (NQ:UTHR)

545.65 +3.95 (+0.73%)

Delayed Quote Updated: 2:19 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Excels as a High-Quality Pick in the Caviar Cruise Stock Screen ↗

August 09, 2025

United Therapeutics Corp (UTHR) excels in the Caviar Cruise stock screen, showcasing strong revenue growth, high ROIC, robust cash flow, and a debt-free balance sheet—ideal for long-term investors.

Via Chartmill

Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Fits Peter Lynch’s Growth at a Reasonable Price (GARP) Strategy ↗

August 06, 2025

UNITED THERAPEUTICS CORP (UTHR) aligns with Peter Lynch's GARP strategy, boasting steady earnings growth (16.88% EPS), low PEG (0.70), zero debt, and strong profitability (17.31% ROE). A solid biotech...

Via Chartmill

Joby Aviation Soars Amidst eVTOL Hype, Signaling a New Era for Air Mobility

August 04, 2025

Joby Aviation (NYSE: JOBY) has recently experienced a significant surge in its stock value, fueled by a burgeoning "aviation buzz" surrounding the electric vertical takeoff and landing (eVTOL) aircraft...

Via MarketMinute

Topics Economy Emissions

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Preview: United Therapeutics's Earnings ↗

July 29, 2025

Via Benzinga

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

August 01, 2025

From United Therapeutics Corporation

Via Business Wire

Forecasting The Future: 8 Analyst Projections For United Therapeutics ↗

July 31, 2025

Via Benzinga

Earnings Summary on United Therapeutics ↗

July 31, 2025

Via The Motley Fool

Topics Intellectual Property

United Therapeutics Stock Slides On Q2 Earnings: The Details ↗

July 30, 2025

United Therapeutics Corp (NASDAQ:UTHR) reported second-quarter financial results before the market open on Wednesday. Here's a rundown of the report.

Via Benzinga

United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates

July 30, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its GAAP profit of $6.41 per share...

Via StockStory

United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results

July 30, 2025

From United Therapeutics Corporation

Via Business Wire

What To Expect From United Therapeutics’s (UTHR) Q2 Earnings

July 28, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? ↗

July 24, 2025

Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.

Via Investor's Business Daily

UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Prime Value Pick with Strong Fundamentals and Undervalued Potential ↗

July 24, 2025

UNITED THERAPEUTICS CORP (UTHR) is a top value stock with strong fundamentals—low P/E, high profitability, zero debt, and steady growth—making it a standout in biotech.

Via Chartmill

Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest

July 16, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the...

Via StockStory

Topics Artificial Intelligence

United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025

July 16, 2025

From United Therapeutics Corporation

Via Business Wire

Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment

July 15, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers.

Via StockStory

Topics Artificial Intelligence

Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)

July 15, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Moderna (NASDAQ:MRNA) and its peers.

Via StockStory

Topics Artificial Intelligence

1 Cash-Producing Stock with Impressive Fundamentals and 2 to Keep Off Your Radar

July 15, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks

July 14, 2025

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.

Via StockStory

Topics Artificial Intelligence

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Strong Candidate for GARP Investors ↗

July 09, 2025

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy.

Via Chartmill

1 Value Stock with Impressive Fundamentals and 2 to Turn Down

July 09, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Potential Undervalued Biotech Stock ↗

July 02, 2025

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a financially healthy biotech stock with strong profitability and an undervalued price. Its low P/E and high margins make it a candidate for value investors.

Via Chartmill

1 Mid-Cap Stock with Exciting Potential and 2 to Ignore

July 01, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

Deep Dive Into United Therapeutics Stock: Analyst Perspectives (9 Ratings) ↗

June 30, 2025

Via Benzinga

Disney To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday ↗

June 30, 2025

Via Benzinga

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

June 24, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

June 23, 2025

From United Therapeutics Corporation

Via Business Wire

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors ↗

June 17, 2025

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers growth at a reasonable price, with strong profitability, no debt, and a PEG ratio of 0.68. A solid pick for long-term investors.

Via Chartmill

AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? ↗

June 15, 2025

11 large-cap stocks were worst performers last week: SJM, CHWY, IOT, UTHR, CVNA, APP, UAL, GRAB, EIX, LULU, MBLY. Analysts lower price forecasts.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.